Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 92

1.

Does Local Ibandronate and/or Pamidronate Delivery Enhance Osseointegration? A Systematic Review.

Kellesarian SV, Abduljabbar T, Vohra F, Gholamiazizi E, Malmstrom H, Romanos GE, Javed F.

J Prosthodont. 2016 Nov 21. doi: 10.1111/jopr.12571. [Epub ahead of print] Review.

PMID:
27870311
2.

A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.

Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M, Strong M, Selby P, Gittoes N.

Health Technol Assess. 2016 Oct;20(78):1-406.

3.

Comparative Efficacy of Bisphosphonates to Prevent Fracture in Men with Osteoporosis: A Systematic Review with Network Meta-Analyses.

Zhou J, Wang T, Zhao X, Miller DR, Zhai S.

Rheumatol Ther. 2016 Jun;3(1):117-128. Epub 2016 Apr 22.

4.

Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses.

Zhou J, Ma X, Wang T, Zhai S.

Osteoporos Int. 2016 Nov;27(11):3289-3300. doi: 10.1007/s00198-016-3654-z. Epub 2016 Jun 7.

PMID:
27273112
5.

Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis.

Sanderson J, Martyn-St James M, Stevens J, Goka E, Wong R, Campbell F, Selby P, Gittoes N, Davis S.

Bone. 2016 Aug;89:52-8. doi: 10.1016/j.bone.2016.05.013. Epub 2016 Jun 1.

PMID:
27262775
6.

GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab.

Hadji P, Kyvernitakis I, Kann PH, Niedhart C, Hofbauer LC, Schwarz H, Kurth AA, Thomasius F, Schulte M, Intorcia M, Psachoulia E, Schmid T.

Osteoporos Int. 2016 Oct;27(10):2967-78. doi: 10.1007/s00198-016-3623-6. Epub 2016 May 12.

7.

Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis.

Ma Z, Li Y, Zhou M, Huang K, Hu H, Liu X, Xu X.

PLoS One. 2016 Mar 1;11(3):e0150203. doi: 10.1371/journal.pone.0150203. eCollection 2016.

8.

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)., Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R.

Lancet. 2015 Oct 3;386(10001):1353-61. doi: 10.1016/S0140-6736(15)60908-4. Epub 2015 Jul 23. Erratum in: Lancet. 2016 Jan 2;387(10013):30.

9.

Dose-Effectiveness Relationships Determining the Efficacy of Ibandronate for Management of Osteoporosis: A Meta-Analysis.

Hou Y, Gu K, Xu C, Ding H, Liu C, Tuoheti Y.

Medicine (Baltimore). 2015 Jul;94(26):e1007. doi: 10.1097/MD.0000000000001007. Review.

10.

Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials.

Geng CJ, Liang Q, Zhong JH, Zhu M, Meng FY, Wu N, Liang R, Yuan BY.

BMJ Open. 2015 Jun 2;5(6):e007258. doi: 10.1136/bmjopen-2014-007258.

11.

Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.

Chen LX, Zhou ZR, Li YL, Ning GZ, Zhang TS, Zhang D, Feng SQ.

PLoS One. 2015 May 26;10(5):e0128032. doi: 10.1371/journal.pone.0128032. eCollection 2015.

12.

Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.

Wang Z, Qiao D, Lu Y, Curtis D, Wen X, Yao Y, Zhao H.

Oncologist. 2015 Apr;20(4):440-9. doi: 10.1634/theoncologist.2014-0328. Epub 2015 Mar 2.

13.

Efficacy, effectiveness and side effects of medications used to prevent fractures.

Reid IR.

J Intern Med. 2015 Jun;277(6):690-706. doi: 10.1111/joim.12339. Erratum in: J Intern Med. 2015 Sep;278(3):333.

PMID:
25495429
14.

New strategies for osteoporosis patients previously managed with strontium ranelate.

Vestergaard P.

Ther Adv Musculoskelet Dis. 2014 Dec;6(6):217-25. doi: 10.1177/1759720X14552070. Review.

15.

Potential role of network meta-analysis in value-based insurance design.

Chambers JD, Winn A, Zhong Y, Olchanski N, Cangelosi MJ.

Am J Manag Care. 2014 Aug;20(8):641-8.

16.

Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods.

Messori A, Fadda V, Maratea D, Trippoli S, Marinai C.

J Endocrinol Invest. 2014 Aug;37(8):769-73. doi: 10.1007/s40618-014-0124-3. Epub 2014 Jul 10.

PMID:
25008458
17.

Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis.

Ellis AG, Reginster JY, Luo X, Cappelleri JC, Chines A, Sutradhar S, Jansen JP.

Value Health. 2014 Jun;17(4):424-32. doi: 10.1016/j.jval.2014.01.008. Epub 2014 May 5.

18.

Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis.

Mandema JW, Zheng J, Libanati C, Perez Ruixo JJ.

J Clin Endocrinol Metab. 2014 Oct;99(10):3746-55. doi: 10.1210/jc.2013-3795. Epub 2014 Jun 10.

PMID:
24915115
19.

Efficacy of systemic bisphosphonate delivery on osseointegration of implants under osteoporotic conditions: lessons from animal studies.

Vohra F, Al-Rifaiy MQ, Almas K, Javed F.

Arch Oral Biol. 2014 Sep;59(9):912-20. doi: 10.1016/j.archoralbio.2014.05.016. Epub 2014 May 16. Review.

PMID:
24908376

Supplemental Content

Loading ...
Support Center